Nothing Special   »   [go: up one dir, main page]

ATE229004T1 - Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung - Google Patents

Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung

Info

Publication number
ATE229004T1
ATE229004T1 AT98400731T AT98400731T ATE229004T1 AT E229004 T1 ATE229004 T1 AT E229004T1 AT 98400731 T AT98400731 T AT 98400731T AT 98400731 T AT98400731 T AT 98400731T AT E229004 T1 ATE229004 T1 AT E229004T1
Authority
AT
Austria
Prior art keywords
nmda receptor
useful
disease
prevention
sulfide derivatives
Prior art date
Application number
AT98400731T
Other languages
English (en)
Inventor
No Sang Park
Churl Min Seong
Young Sik Jung
Jin Il Choi
Chang Woo Lee
Yong Jun Chung
Seung Won Choi
Jae Yang Kong
Dong
Woo Kyu Park
Original Assignee
Korea Res Inst Chem Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019970011958A external-priority patent/KR19980075708A/ko
Priority claimed from KR1019970013818A external-priority patent/KR100236466B1/ko
Priority claimed from KR1019970058546A external-priority patent/KR100301129B1/ko
Application filed by Korea Res Inst Chem Tech filed Critical Korea Res Inst Chem Tech
Application granted granted Critical
Publication of ATE229004T1 publication Critical patent/ATE229004T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT98400731T 1997-03-31 1998-03-27 Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung ATE229004T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1019970011958A KR19980075708A (ko) 1997-03-31 1997-03-31 Nmda 수용체 길항제로 작용하는 3-아릴티오-4-하이드록시퀴놀린-2(1h)-온 유도체 및 그들의 제조방법
KR1019970013818A KR100236466B1 (ko) 1997-04-15 1997-04-15 Nmda 수용체 길항제로 작용하는 3-헤테로사이클릭 메르캅토-4-하이드록시퀴놀린-2(1h)-온 유도체 및 그들의 제조방법
KR1019970058546A KR100301129B1 (ko) 1997-11-06 1997-11-06 3-(치환-페닐티오)-4-하이드록시퀴놀린-2(1h)-온 유도체 및 그들의 제조방법

Publications (1)

Publication Number Publication Date
ATE229004T1 true ATE229004T1 (de) 2002-12-15

Family

ID=27349502

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98400731T ATE229004T1 (de) 1997-03-31 1998-03-27 Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung

Country Status (5)

Country Link
US (1) US5990126A (de)
EP (1) EP0869122B1 (de)
JP (1) JP3130502B2 (de)
AT (1) ATE229004T1 (de)
DE (1) DE69809827D1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2317688T3 (es) * 1998-01-29 2009-04-16 Amgen Inc. Moduladores ppar-gamma.
US6583157B2 (en) * 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
JP2000291403A (ja) 1999-04-02 2000-10-17 Toshiba Corp 蒸気タービン
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
JP4592130B2 (ja) * 1999-08-05 2010-12-01 大塚化学株式会社 チオ酢酸アミド化合物及び農園芸用殺菌剤
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
WO2001092925A1 (fr) * 2000-05-31 2001-12-06 Mitsui Chemicals, Inc. Materiau optique et element optique contenant un compose de sulfure aromatique et compose de sulfure aromatique
US20030171399A1 (en) * 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
EP1436258A4 (de) * 2001-03-08 2005-03-23 Univ Emory Ph-wert-abhängige nmda-rezeptorantagonisten
US20030022253A1 (en) * 2001-07-25 2003-01-30 Nyxis Neurotherapies, Inc. Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US20050250820A1 (en) * 2004-03-08 2005-11-10 Amgen Inc. Therapeutic modulation of PPARgamma activity
US8916550B2 (en) * 2005-05-09 2014-12-23 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
US7803790B2 (en) * 2005-05-09 2010-09-28 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
WO2008033564A1 (en) 2006-09-15 2008-03-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
WO2009006437A1 (en) 2007-06-29 2009-01-08 Emory University Nmda receptor antagonists for neuroprotection
SG193793A1 (en) * 2008-08-12 2013-10-30 Zinfandel Pharmaceuticals Inc Method of identifying disease risk factors
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
AU2009330745B2 (en) 2008-12-24 2012-04-05 Astrazeneca Ab Ethanamine compounds and their use for treating depression
EP3106165B1 (de) 2011-01-10 2019-02-27 Zinfandel Pharmaceuticals, Inc. Verfahren und arzneimittelprodukte zur behandlung von morbus alzheimer
KR101197618B1 (ko) 2012-03-13 2012-11-07 한국화학연구원 결핵의 예방 또는 치료용 약제학적 조성물
EP4096661A4 (de) 2020-01-29 2024-03-06 Kamari Pharma Ltd. Verbindungen und zusammensetzungen zur verwendung beim behandeln von hauterkrankungen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127574A (en) * 1976-03-01 1978-11-28 Sandoz, Inc. 4-Hydroxy-3-sulfonyl-quinolin-2(1H)-ones
US4121587A (en) * 1977-03-03 1978-10-24 National Patent Development Corporation Root canal delivery syringe
DE69113115T2 (de) * 1990-05-31 1996-06-13 Merck Sharp & Dohme Dioxo-tetrahydrochinolinderivate.
GB9022785D0 (en) * 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
GB9026389D0 (en) * 1990-12-05 1991-01-23 Merck Sharp & Dohme Therapeutic agents
US5622965A (en) * 1993-03-12 1997-04-22 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon 4-hydroxy-3-nitro-1,2-dihydroquinolin-2-ones and the use thereof as excitatory amino acid and glycine receptor antagonists
EP0685466A1 (de) * 1994-06-02 1995-12-06 Ciba-Geigy Ag 3-Heteroaliphatyl- und 3-Hetero-(aryl)aliphatyl-2(1H)-chinolonderivate

Also Published As

Publication number Publication date
EP0869122A1 (de) 1998-10-07
JP3130502B2 (ja) 2001-01-31
US5990126A (en) 1999-11-23
EP0869122B1 (de) 2002-12-04
DE69809827D1 (de) 2003-01-16
JPH10310575A (ja) 1998-11-24

Similar Documents

Publication Publication Date Title
ATE229004T1 (de) Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
CY1108674T1 (el) Κυκλικα αμιδια
DE69628051D1 (de) Phenylethanolamin-verbindungen und ihre anwendung als beta3 agonisten, verfahren zu ihrer herstellung und zwischenprodukte ihrer herstellung
WO1993011115A3 (en) Quinolone derivatives and their use as nmda and ampa receptor antagonists
DE69619479D1 (de) Azaheterocyclische Tachykinin Rezeptor Antagoniste; NK1 und NK2
NO20071967L (no) Imidazo-benzodiazepinderivater
ES2195943T3 (es) Compuestos heteroaromaticos biciclicos y triciclicos.
WO1997020823A3 (en) 2-amino quinazoline derivatives as npy receptor antagonists
GEP20104959B (en) Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
ATE289310T1 (de) Heteroaryl-diazabicycloalkanderivaten als cns- modulatoren
ES2092639T3 (es) Mejoras en o relativas a antagonistas de receptores de aminoacidos excitatorios.
WO2006017409A3 (en) 1,3-disubstituted heteroaryl nmda/nr2b antagonists
ATE466858T1 (de) 3-arylisoxazol-4-carbonylbenzofuranderivative
MXPA04006184A (es) Compuestos derivados de 1h-pirazolilo, para el uso en enfermedades asociadas con el receptor 5-ht2c.
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
DK1578740T3 (da) 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
ATE352543T1 (de) Ein dioxino(2,3-g)chinolin-9-carbonsäure derivat als nk3 rezeptor antagonist
WO2003095432A1 (fr) Derives de benzimidazole
RS20050892A (en) Imidazole derivatives as glutamate receptor antagonists
DE60112574D1 (de) Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten
WO2003057213A3 (en) Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
ATE398614T1 (de) Triazolverbindungen und ihre therapeutische verwendung
BR9712577A (pt) Derivado de benzoxazola

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties